A30 BIOMARKERS IN THORACIC ONCOLOGY: PREDICTING OUTCOMES: Mass Spectrometry Based Proteomic Analysis For Prognostication In Lung Cancer

A30 BIOMARKERS IN THORACIC ONCOLOGY: PREDICTING OUTCOMES: Mass Spectrometry Based Proteomic Analysis For Prognostication In Lung Cancer

Despite multibillion dollar research in discovery of newer treatment options, the overall five-year survival rate remains very poor. [...]there is a need for predictive tests that can identify which therapies are most appropriate for individual patients and assess their outcome. [...]prevalence of E...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of respiratory and critical care medicine 2017-01, Vol.195
Hauptverfasser: Ratcliff, S, Ifeacho, V, Santiago, T, Upadhyay, D, Peterson, M
Format: Artikel
Sprache:eng
Schlagworte:
Lung cancer
Mass spectrometry
Medical prognosis
Mutation
Patients
Scientific imaging
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title American journal of respiratory and critical care medicine
container_volume 195
creator Ratcliff, S
Ifeacho, V
Santiago, T
Upadhyay, D
Peterson, M
description Despite multibillion dollar research in discovery of newer treatment options, the overall five-year survival rate remains very poor. [...]there is a need for predictive tests that can identify which therapies are most appropriate for individual patients and assess their outcome. [...]prevalence of EGFR mutation is
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1926867628</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1926867628</sourcerecordid><originalsourceid>FETCH-proquest_journals_19268676283</originalsourceid><addsrcrecordid>eNqNjMtqwkAYRgdpQXt5hx-6Dkwu5uIuTqMONRlJUmhXMsRRIjpj558sfIK-di30Abr6DofDNyITfxpOvShL6N2NaRJ6UZR9jMkD4pFSP0h9OiHfeUhhzkWZ129F3QCvoF2JOmecgaiYWIvl5ww2dfHKWcurJYj3lomyaGZQSkRoLqpz1pyVs1eYS1Q72FjjlDn3HeRanq7YIyyM_dUHbdD1nXS90cA1rAd9ACZ1p-wTud_LE6rnv30kL4uiZSvvYs3XoNBtj2awtz_c-lkQp3ESB2n4v-oHfBFPBg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1926867628</pqid></control><display><type>article</type><title>A30 BIOMARKERS IN THORACIC ONCOLOGY: PREDICTING OUTCOMES: Mass Spectrometry Based Proteomic Analysis For Prognostication In Lung Cancer</title><source>Journals@Ovid Complete</source><source>American Thoracic Society (ATS) Journals Online</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Ratcliff, S ; Ifeacho, V ; Santiago, T ; Upadhyay, D ; Peterson, M</creator><creatorcontrib>Ratcliff, S ; Ifeacho, V ; Santiago, T ; Upadhyay, D ; Peterson, M</creatorcontrib><description>Despite multibillion dollar research in discovery of newer treatment options, the overall five-year survival rate remains very poor. [...]there is a need for predictive tests that can identify which therapies are most appropriate for individual patients and assess their outcome. [...]prevalence of EGFR mutation is &lt;18% in any given population per lung cancer consortium. Since majority of NSCLC cases do not harbor activating mutations in the EGFR gene, this test needs to be assessed in all patients with NSCLC.</description><identifier>ISSN: 1073-449X</identifier><identifier>EISSN: 1535-4970</identifier><language>eng</language><publisher>New York: American Thoracic Society</publisher><subject>Lung cancer ; Mass spectrometry ; Medical prognosis ; Mutation ; Patients ; Scientific imaging</subject><ispartof>American journal of respiratory and critical care medicine, 2017-01, Vol.195</ispartof><rights>Copyright American Thoracic Society 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Ratcliff, S</creatorcontrib><creatorcontrib>Ifeacho, V</creatorcontrib><creatorcontrib>Santiago, T</creatorcontrib><creatorcontrib>Upadhyay, D</creatorcontrib><creatorcontrib>Peterson, M</creatorcontrib><title>A30 BIOMARKERS IN THORACIC ONCOLOGY: PREDICTING OUTCOMES: Mass Spectrometry Based Proteomic Analysis For Prognostication In Lung Cancer</title><title>American journal of respiratory and critical care medicine</title><description>Despite multibillion dollar research in discovery of newer treatment options, the overall five-year survival rate remains very poor. [...]there is a need for predictive tests that can identify which therapies are most appropriate for individual patients and assess their outcome. [...]prevalence of EGFR mutation is &lt;18% in any given population per lung cancer consortium. Since majority of NSCLC cases do not harbor activating mutations in the EGFR gene, this test needs to be assessed in all patients with NSCLC.</description><subject>Lung cancer</subject><subject>Mass spectrometry</subject><subject>Medical prognosis</subject><subject>Mutation</subject><subject>Patients</subject><subject>Scientific imaging</subject><issn>1073-449X</issn><issn>1535-4970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNjMtqwkAYRgdpQXt5hx-6Dkwu5uIuTqMONRlJUmhXMsRRIjpj558sfIK-di30Abr6DofDNyITfxpOvShL6N2NaRJ6UZR9jMkD4pFSP0h9OiHfeUhhzkWZ129F3QCvoF2JOmecgaiYWIvl5ww2dfHKWcurJYj3lomyaGZQSkRoLqpz1pyVs1eYS1Q72FjjlDn3HeRanq7YIyyM_dUHbdD1nXS90cA1rAd9ACZ1p-wTud_LE6rnv30kL4uiZSvvYs3XoNBtj2awtz_c-lkQp3ESB2n4v-oHfBFPBg</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Ratcliff, S</creator><creator>Ifeacho, V</creator><creator>Santiago, T</creator><creator>Upadhyay, D</creator><creator>Peterson, M</creator><general>American Thoracic Society</general><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20170101</creationdate><title>A30 BIOMARKERS IN THORACIC ONCOLOGY: PREDICTING OUTCOMES: Mass Spectrometry Based Proteomic Analysis For Prognostication In Lung Cancer</title><author>Ratcliff, S ; Ifeacho, V ; Santiago, T ; Upadhyay, D ; Peterson, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_19268676283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Lung cancer</topic><topic>Mass spectrometry</topic><topic>Medical prognosis</topic><topic>Mutation</topic><topic>Patients</topic><topic>Scientific imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ratcliff, S</creatorcontrib><creatorcontrib>Ifeacho, V</creatorcontrib><creatorcontrib>Santiago, T</creatorcontrib><creatorcontrib>Upadhyay, D</creatorcontrib><creatorcontrib>Peterson, M</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>American journal of respiratory and critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ratcliff, S</au><au>Ifeacho, V</au><au>Santiago, T</au><au>Upadhyay, D</au><au>Peterson, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A30 BIOMARKERS IN THORACIC ONCOLOGY: PREDICTING OUTCOMES: Mass Spectrometry Based Proteomic Analysis For Prognostication In Lung Cancer</atitle><jtitle>American journal of respiratory and critical care medicine</jtitle><date>2017-01-01</date><risdate>2017</risdate><volume>195</volume><issn>1073-449X</issn><eissn>1535-4970</eissn><abstract>Despite multibillion dollar research in discovery of newer treatment options, the overall five-year survival rate remains very poor. [...]there is a need for predictive tests that can identify which therapies are most appropriate for individual patients and assess their outcome. [...]prevalence of EGFR mutation is &lt;18% in any given population per lung cancer consortium. Since majority of NSCLC cases do not harbor activating mutations in the EGFR gene, this test needs to be assessed in all patients with NSCLC.</abstract><cop>New York</cop><pub>American Thoracic Society</pub></addata></record>
fulltext fulltext
identifier ISSN: 1073-449X
ispartof American journal of respiratory and critical care medicine, 2017-01, Vol.195
issn 1073-449X
1535-4970
language eng
recordid cdi_proquest_journals_1926867628
source Journals@Ovid Complete; American Thoracic Society (ATS) Journals Online; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Lung cancer
Mass spectrometry
Medical prognosis
Mutation
Patients
Scientific imaging
title A30 BIOMARKERS IN THORACIC ONCOLOGY: PREDICTING OUTCOMES: Mass Spectrometry Based Proteomic Analysis For Prognostication In Lung Cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T01%3A33%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A30%20BIOMARKERS%20IN%20THORACIC%20ONCOLOGY:%20PREDICTING%20OUTCOMES:%20Mass%20Spectrometry%20Based%20Proteomic%20Analysis%20For%20Prognostication%20In%20Lung%20Cancer&rft.jtitle=American%20journal%20of%20respiratory%20and%20critical%20care%20medicine&rft.au=Ratcliff,%20S&rft.date=2017-01-01&rft.volume=195&rft.issn=1073-449X&rft.eissn=1535-4970&rft_id=info:doi/&rft_dat=%3Cproquest%3E1926867628%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1926867628&rft_id=info:pmid/&rfr_iscdi=true